Dima Shulkin: A Novel Monocyte-Based Biomarker of Cardiovascular Risk
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn:
“What if a simple blood test could flag hidden heart disease long before any symptoms appear?
A 2024 medRxiv preprint by Almarri and colleagues (not yet peer-reviewed) explored exactly that.
They studied symptom-free adults, first a small group of 39, then 151 more in Nanjing, China, measuring immune cells called monocytes (part of the body’s defense team) and how often they clump with platelets.
The readings became a new score, MARS, which tracked real artery damage far more closely than the standard risk calculators doctors use now.
Early research, but a real hint that a blood sample may reveal what checklists miss.”
Other posts featuring Dima Shulkin on Hemostasis Today.
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day
-
Oct 17, 2026, 23:18Maha Othman: Establishing ISTH-BAT Reference Ranges for Children and Adolescents
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland